
SXTP Stock Forecast & Price Target
SXTP Analyst Ratings
Bulls say
60 Degrees is showing positive clinical progress in their development of tafenoquine for Babesiosis, with all patients in the expanded-access study being cured and enrollment underway for the chronic Babesiosis Phase II study. The company also saw strong growth in ARAKODA sales in FY25 and raised additional funding through ATM sales. With a pipeline of promising products and a potentially underserved market for infectious disease treatments, there is potential for the stock to see significant upside in the near term, although risks such as regulatory approvals and potential dilution from future financings should be considered.
Bears say
60 Degrees is struggling to generate significant revenue with a slow quarter in FY25, while its growth potential from a recent partnership with Runway Health and its strong pipeline of products targeting various infectious diseases may lead to growth potential in the future. Their focus on expanding ARAKODA's access and a new phase 2 Babesiosis study could be positive catalysts, but it is still important to monitor the company's financial performance and competition in the market before considering investing.
This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
SXTP Analyst Forecast & Price Prediction
Start investing in SXTP
Order type
Buy in
Order amount
Est. shares
0 shares